

**Sun Pharmaceutical Industries Limited**

SUN HOUSE, CTS No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
CIN: L24230GJ1993PLC019050  
www.sunpharma.com



**30 March 2022.**

**National Stock Exchange of India Limited,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai- 400 051

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001

**Scrip Symbol: SUNPHARMA**

**Scrip Code: 524715**

**Sub:** Press Release

Dear Sir / Madam,

Please find enclosed herewith our Press Release on Sun Pharma introducing its version of Vortioxetine in India, which we shall be releasing after sending this letter to you.

This is for your information and dissemination.

Thanking you,

Yours faithfully,

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)

**Company Secretary and Compliance Officer**

Enclosed: As above



**FOR IMMEDIATE RELEASE**

## **Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck**

Mumbai, India, March 30, 2022 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that one of its wholly-owned subsidiaries has entered into an exclusive patent licensing agreement with H. Lundbeck A/S (“Lundbeck”) to market and distribute its own version of Vortioxetine in India under the brand name, VORTIDIF™. The territory of the licensing agreement will only cover India.

Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in over 80 countries<sup>1</sup>, including the US, EU, Canada and Australia.

Kirti Ganorkar, CEO of India Business, Sun Pharma, said, “Sun Pharma is the leader in the neuro-psychiatry therapy in India and we always endeavour to bring innovative medicines that fill a need gap. MDD is a serious and complicated disorder and VORTIDIF™ will serve as an important novel treatment option for patients in India.”

MDD is one of the leading cause of disability, affecting approximately 246 million people globally<sup>2</sup> and 35 million people in India.<sup>3</sup> MDD is characterised by pronounced changes in mood coupled with distinct psychological and vegetative changes, including sleep, appetite disturbance, subjective fatigue, loss of motivation and drive, ruminative feelings of guilt and despair, problems maintaining mental focus, and suicidal thinking and behaviour.<sup>4</sup>

Sun Pharma is ranked No. 1 by prescriptions and value amongst Neurologists & Psychiatrists in India (IMS MAT Jan 2022). With a strong product portfolio, Sun Pharma’s CNS division constantly strives to provide innovative solutions to patients and health care providers in India.

[H. Lundbeck](#) is a global pharmaceutical company specialising in brain diseases.

*TM - All brand names and trademarks are the property of their respective owners.*

### **References:**

1. [Lundbeck](#)
2. COVID-19 Mental Disorders Collaborators. Lancet. 2021 Nov 6;398(10312):1700-1712.
3. Arvind BA, et.al. BMJ Open. 2019 Jun 27;9(6): e027250.
4. Kelliny M, et.al. Ther Clin Risk Manag. 2015;11:1193-1212. Published 2015 Aug 12.

Sun Pharmaceutical Industries Limited  
SUN HOUSE, CTS No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
CIN: L24230GJ1993PLC019050  
www.sunpharma.com



**Disclaimer:**

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

**About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050)**

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across six continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D. For further information, please visit [www.sunpharma.com](http://www.sunpharma.com) and follow us on Twitter @SunPharma\_Live.

**Contacts:**

**Investors:**

Nimish Desai  
Tel +91 22 4324 4324, Xtn 2778  
Tel Direct +91 22 4324 2778  
**Mobile** +91-98203 30182  
**E mail** [nimish.desai@sunpharma.com](mailto:nimish.desai@sunpharma.com)

**Media:**

Gaurav Chugh  
Tel +91 22 4324 4324, Xtn 5373  
Tel Direct +91 22 4324 5373  
**Mobile** +91 98104 71414  
**E mail** [gaurav.chugh@sunpharma.com](mailto:gaurav.chugh@sunpharma.com)